Roche presents new data for TECENTRIQ® (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017
Basel, 03 June 2017 Roche presents new data for TECENTRIQ® (atezolizumab) and updates from across its cancer immunotherapy development programme at ASCO 2017 Data evaluated TECENTRIQ in novel combinations across a broad range of tumours including lung, kidney and melanoma Promising Phase II combination data with TECENTRIQ plus Avastin (bevacizumab) in advanced kidney cancer First... Read more